argenx SE (NASDAQ:ARGX) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC increased its holdings in shares of argenx SE (NASDAQ:ARGX) by 0.6% in the third quarter, Holdings Channel reports. The firm owned 237,966 shares of the company’s stock after acquiring an additional 1,528 shares during the period. Jennison Associates LLC’s holdings in argenx were worth $128,997,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of argenx by 49.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after purchasing an additional 439,889 shares during the period. Perpetual Ltd acquired a new stake in shares of argenx in the third quarter valued at approximately $76,314,000. Logos Global Management LP bought a new position in shares of argenx in the second quarter valued at approximately $58,055,000. Finally, Sei Investments Co. boosted its holdings in shares of argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after acquiring an additional 50,477 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ARGX shares. Wells Fargo & Company increased their price objective on shares of argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and raised their price objective for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Guggenheim raised their price objective on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Wedbush increased their target price on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Finally, William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.79.

argenx Stock Up 1.2 %

Shares of ARGX opened at $574.54 on Wednesday. argenx SE has a 52 week low of $327.73 and a 52 week high of $611.22. The stock has a market cap of $34.36 billion, a price-to-earnings ratio of -652.89 and a beta of 0.61. The business has a 50-day simple moving average of $553.99 and a two-hundred day simple moving average of $485.19.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the business posted ($1.25) earnings per share. On average, equities analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.